Novartis COPD Drug Wil Test The LABA Safety Waters During Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Given the known risks of long-acting beta-2 agonists, a safety discussion seems likely when the Pulmonary-Allergy Drugs Advisory Committee meets to review Novartis' Arcapta Neohaler (indacaterol maleate).
You may also be interested in...
The once-daily COPD treatment, already approved in Europe with ho-hum sales, is a lynchpin of Novartis' plan to establish a respiratory franchise.
Discussions about how best to study the safety of long-acting beta agonists are ready to resume now that FDA has issued a revised label for the drug class
Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting